Appeals Court Upholds Ruling Favoring Transkaryotic in Patent Suit

Law360, New York (October 12, 2003, 12:00 AM EDT) -- An appeals court upheld a ruling that Transkaryotic Therapies Inc. didn't infringe on patents related to its Fabry disease treatment, Dow Jones Newswires reported.

Only a day earlier, Genzyme Corp. pulled out of the litigation as part of a settlement. Genzyme and Mount Sinai School of Medicine claimed that Transkaryotic's main product, Replagal, infringed on one of their patents.

A Delaware district court dismissed the lawsuit in January 2002, and Genzyme and Mount Sinai appealed the decision in March of that year.

As part of the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.